Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3323-3330

  Kai, Li ^a,b   Levenson, Anait S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Androgen receptor; Combination strategy; Flutamide; Prostate cancer; Prostate specific antigen; Resveratrol

Indexed keywords

ANDROGEN RECEPTOR; FLUTAMIDE; MESSENGER RNA; RESVERATROL;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; DRUG POTENTIATION; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXIMIDE; DIHYDROTESTOSTERONE; DOWN-REGULATION; DRUG SYNERGISM; FLUTAMIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; RNA, MESSENGER; STILBENES; TRANSCRIPTIONAL ACTIVATION;

EID: 80054724906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fletterick RJ: Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer. BJU Int 96(Suppl 2): 2-9, 2005.
2. Kokontis JM and Liao S: Molecular action of androgen in the normal and neoplastic prostate. Vitam Horm 55: 219-307, 1999.
3. Kageyama Y, Hyochi N, Kihara K and Sugiyama H: The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Pat Anticancer Drug Discov 2: 203-211, 2007. (Pubitemid 350200262)
4. Schoonen WM, Salinas CA, Kiemeney LA and Stanford JL: Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113: 133-140, 2005. (Pubitemid 39507320)
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997. (Pubitemid 127696281)
6. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellon EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28: 282-293, 2007. (Pubitemid 46423911)
7. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER and Reddy GP: Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 62: 2488-2492, 2002. (Pubitemid 34462723)
8. Kai L, Samuel SK and Levenson AS: Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 126: 1538-1548, 2010.
9. Kozuki Y, Miura Y and Yagasaki K: Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett 167: 151-156, 2001. (Pubitemid 32706677)
10. Kimura Y and Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131: 1844-1849, 2001. (Pubitemid 32520456)
11. Brakenhielm E, Cao R and Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 15: 1798-1800, 2001.
12. Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, Mirochnik Y, Satcher RL Jr. and Levenson AS: Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1). Prostate 71: 268-280, 2011.
13. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE, 3rd, Jameson JL and Jordan VC: Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer 104: 587-596, 2003. (Pubitemid 36337258)
14. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
15. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004. (Pubitemid 39409568)
16. Narayanan BA, Narayanan NK, Re GG and Nixon DW: Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 104: 204-212, 2003. (Pubitemid 36249796)
17. Hsieh TC and Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999.
18. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, Lin PY and Chen Y: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 10: 2190-2202, 2004.
19. Moyad MA and Carroll PR: Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am 31: 289-300, 2004. (Pubitemid 38584594)
20. Syed DN, Khan N, Afaq F and Mukhtar H: Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 16: 2193-2203, 2007. (Pubitemid 351196348)
21. Shi WF, Leong M, Cho E, Farrell J, Chen HC, Tian J and Zhang D: Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 4: e7398, 2009.
22. Mitchell SH, Zhu W and Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895, 1999. (Pubitemid 30004946)
23. Hsieh TC and Wu JM: Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 20: 225-228, 2000.
24. Furutani T, Watanabe T, Tanimoto K, Hashimoto T, Koutoku H, Kudoh M, Shimizu Y, Kato S and Shikama H: Stabilization of androgen receptor protein is induced by agonist, not by antagonists. Biochem Biophys Res Commun 294: 779-784, 2002. (Pubitemid 34687184)
25. Harada N, Murata Y, Yamaji R, Miura T, Inui H and Nakano Y: Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 53: 556-560, 2007. (Pubitemid 351154880)
26. Sheflin L, Keegan B, Zhang W and Spaulding SW: Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276: 144-150, 2000.
27. Lin HK, Hu YC, Lee DK and Chang C: Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18: 2409-2423, 2004. (Pubitemid 39335977)
28. Kemppainen JA, Lane MV, Sar M and Wilson EM: Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267: 968-974, 1992.
29. Wong CI, Zhou ZX, Sar M and Wilson EM: Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem 268: 19004-19012, 1993. (Pubitemid 23273853)
30. Bowers JL, Tyulmenkov VV, Jernigan SC and Klinge CM: Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667, 2000.
31. Wang TT, Hudson TS, Wang TC, Remsberg CM, Davies NM, Takahashi Y, Kim YS, Seifried H, Vinyard BT, Perkins SN and Hursting SD: Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 29: 2001-2010, 2008.
32. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 223-233, 2000.
33. Yuan H, Pan Y and Young CY: Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 213: 155-163, 2004. (Pubitemid 39140973)
34. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH and Gleave ME: Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 272: 17485-17494, 1997. (Pubitemid 27311181)
35. Harada N, Atarashi K, Murata Y, Yamaji R, Nakano Y and Inui H: Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor. J Steroid Biochem Mol Biol 123: 65-70, 2011.